zuChem Expands Scientific Advisory Board; Additional Pharmaceutical and Biotech Expertise To Enhance Pharmaceutical Strategy and Research Programs

CHICAGO, Jun 7, 2004 -- zuChem, Inc., an innovative supplier of glycochemicals and other specialized sugars for the pharmaceutical, food, nutraceutical, and related industries, today announced the expansion of its scientific expertise with the appointments of Robin Cooper, Ph.D., and William Dowd, Ph.D. to its Scientific Advisory Board. The company recruited these senior advisors to help guide the company's pharmaceutical strategy and research programs.

"As our first pharmaceutical and food products move closer toward commercialization, we felt it was important to add complimentary skills to our already strong Scientific Advisory Board," said David Demirjian, Ph.D, CEO of zuChem. "Dr. Cooper and Dr. Dowd bring valuable experience to our board, having developed significant products while with two of the most successful companies in the life sciences industry. Their experience and insight will provide additional direction for our pharmaceutical product development strategy and research programs."

"zuChem's technology has the potential to create significant value for pharmaceutical companies in new drug candidate identification, and also process development," said Dr. Cooper. "The use of scalable glycochemical-type pharmaceutical intermediates will create new opportunities for developing and producing new anti-cancer, anti-viral, anti-microbial and other drugs. I'm pleased to have the opportunity to contribute to their programs."

Robin Cooper, Ph.D., D.Sc.

Dr. Cooper brings more than 30 years of pharmaceutical development experience to zuChem. He recently joined Rigel Pharmaceuticals as senior vice president of Pharmaceutical Sciences. Previously, throughout a more than 30-year career at Eli Lilly and Company, Dr. Cooper held a number of senior chemistry development research positions, in which he made significant contributions to developing Lilly's preeminent position in anti-infectives. He also discovered oritavancin, an anti-infective that was licensed to InterMune, Inc. and is presently in phase III clinical trials.

Dr. Cooper received his Ph.D. in 1962 from Queen Mary College/Imperial College, followed by a year with Nobel Laureate Sir Derek Barton in London. He was awarded a D.Sc. by the University of London in 1985.

William Dowd, Ph.D.

Dr. Dowd retired in 2000 as the global R&D director for Industrial Biotechnology for Dow Chemical where he had responsibility for the technology focus of Dow's biotechnology commercial activities. During a more than 30-year tenure at Dow, he held a wide range of process research and corporate R&D positions including director of the Materials R&D laboratory, and platform leader, BioMaterials. He is currently also a member of the Board of Directors of Neoprobe Corporation and the Biotechnology Research and Development Corporation.

Dr. Dowd received his Ph.D. in 1970 in Physical-Organic Chemistry from Indiana University.

About zuChem, Inc.

zuChem, Inc. is focused on the commercialization of innovative manufacturing processes for unique glycochemicals (varieties of specialized sugars and sugar-derivatives) for the pharmaceutical, food, agriculture, flavor and fragrances, and specialty chemicals industries. Glycochemicals are key components of many antibiotics, anticancer and antiviral drugs, as well as many food ingredients. The company is based in Chicago, Ill. and has research operations in Peoria, Ill.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.